Using a hepatocellular carcinoma model system, the antitumoral role of CD169+Mφs could be further supported by the finding that CD169+ Mφs exhibited an activated phenotype and promoted Th1/Tc1 cell responses via CD169-medicated Mφ–T cell interactions (unpublished observations). The gene discussed is SIGLEC1; the disease is hepatocellular carcinoma.